Relative Intelligence · Life Sciences Tools

How Agilent Technologies (A) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on A alone. It places A (Agilent Technologies, Inc.) against 18 popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where A stands in the market, and of the alternatives worth a closer look.
Period covered: A's full trading record, from November 1999 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowA has run far ahead of the market, rising 43.6% over the past 6 months against 9.1% for the S&P 500 and 11.2% for the Nasdaq 100. Its life sciences tool peers were far apart over the past 6 months, from ILMN (Illumina, up 102%) to DHR (Danaher, up 15.0%). Consistency ↓
- Stock or market?A's 33.1% gain over the past 3 months far outran its industry: the life sciences tools ETF IHI (iShares U.S. Medical Devices ETF) rose 7.5%. The S&P 500 rose 3.9%. Its life sciences tool peers did not move as one over the past 3 months: AVTR (Avantor) rose 55.9%, while DHR (Danaher) rose 11.6%.
- Past 1 to 3 yearsOver the past year, A rose 22.0% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. Even so, A finished behind the S&P 500 in both 2024 and 2025. By year ↓
- Long termA turned $10,000 into $40,600 over the past decade, against $42,100 in the S&P 500. That said, over the past decade, only TMO (Thermo Fisher Scientific) of its life sciences tool peers outpaced A. Growth of $10,000 ↓
- In a crashAcross seven sell-offs, A has typically fallen 1.3 times as far as the S&P 500. Crash tests ↓
- DiversificationA is more of the same, not a cushion: a correlation of 0.64 with the S&P 500 over 5 years and 0.65 with the total US market, more closely than 95% of stocks worth at least $300 million. Market capture ↓
- Better options
- Popular alternatives
- AMGN (Amgen) earned more than A with less volatility over the past 5 years: 19.6% a year at 24.9% volatility, against 2.6% a year at 30.6%.
- Nearby categories and themes
- JNJ (Johnson & Johnson, pharmaceuticals) and NVS (Novartis, pharmaceuticals) earned more than A with less volatility over the past 5 years. JNJ returned 12.7% a year at 17.9% volatility, against 2.6% a year at 30.6%.
- Versus the S&P 500
- Simply owning the S&P 500 would have done better over the past 5 years: 12.7% a year at 17.1% volatility, against 2.6% at 30.6% for A.
How much would $10,000 in A have grown?
This chart tracks a hypothetical $10,000 investment in A over the past 26 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of A over the same span and A's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in A at the end of September 2000 would have grown to $59,185 by September 2026, less than the $84,332 it would have become in SPY, an S&P 500 fund.
- Six of the eight other investments on the chart ended ahead of A, and TMO finished highest, at $362,153.
Choose a period
From the end of September 2000 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 830 of the 1,261 stocks and funds worth at least $500 million that traded the whole period ended ahead of A; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- TMO$362,153+3,522% total · +14.8% a year
- MTD$343,384+3,334% total · +14.6% a year
- LLY$284,700+2,747% total · +13.7% a year
- ILMN$124,118+1,141% total · +10.2% a year
- AMGN$90,435+804% total · +8.8% a year
- CRL$86,769+768% total · +8.7% a year
- SPY (S&P 500)$84,332+743% total · +8.5% a year
- A$59,185+492% total · +7.1% a year
- WAT$49,371+394% total · +6.3% a year
- RVTY$37,181+272% total · +5.2% a year
From the end of September 2021 to the end of September 2026. Hover over a fund in the key to pick out its line. 2,256 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of A; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- LLY$52,411+424% total · +39.3% a year
- MEDP$32,977+230% total · +27.0% a year
- GILD$25,496+155% total · +20.6% a year
- AMGN$23,160+132% total · +18.3% a year
- NVS$21,146+111% total · +16.2% a year
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- JNJ$18,849+88.5% total · +13.5% a year
- WAT$12,298+23.0% total · +4.2% a year
- TMO$11,986+19.9% total · +3.7% a year
- A$11,334+13.3% total · +2.5% a year
A at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- A's deepest decline since it began trading in 1999 was 93.2%, from March 2000 to October 2002. It took about 18 years from the low to climb back to its old high.
- Over 26 full calendar years, A's best was 2009, when it returned 98.7%, and its worst was 2008, when it lost 57.4%. It lost money in nine of those years.
- A is 1.4% below its all-time high.
The company
- Market value
- $49B
- Industry
- Medical - Diagnostics & Research
- Price history from
- November 1999
Returns
- Past 1 year
- +22.0%total return
- Past 3 years
- +62.1%+17.5% a year
- Past 5 years
- +13.8%+2.6% a year
- Past 10 years
- +306%+15.0% a year
- Best calendar year
- +98.7%2009
- Worst calendar year
- −57.4%2008
- Losing years
- 9 of 26full calendar years
Risk
- Volatility
- 30.6%typical yearly swing, 5 years
- Sharpe ratio
- 0.24return per unit of risk, 5 years
- Worst decline ever
- −93.3%Mar 2000 to Oct 2002
- From its all-time high
- −1.4%below the peak
A against the whole market
Where A ranks among every stock and fund, and what across the market has done better.
How does A rank among all stocks?
This section ranks A on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how A stacks up against its peers, these rankings show where it stands in the market as a whole.
- A's worst decline of the past 10 years ranks in the top 11% of the 2,187 stocks worth at least $300 million, where the top fell the least.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | A | Rank | Standing |
|---|---|---|---|
| 1-year return | +22.0% | 1,186 of 3,287 | top 36% |
| 3-year return | +62.1% | 1,374 of 3,017 | top 46% |
| 5-year return | +13.8% | 1,541 of 2,893 | bottom 48% |
| 10-year return | +306% | 573 of 2,202 | top 26% |
| Volatility, 5 years | 30.6% | 788 of 2,893 | top 27% |
| Sharpe ratio, 5 years | 0.24 | 1,743 of 2,893 | bottom 41% |
| Worst decline, past 10 years | −43.2% | 234 of 2,187 | top 11% |
What has beaten A on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). A sits where the dashed lines cross. Anything in the green box above and to the left earned more than A with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 375 stocks and 699 ETFs worth at least $500 million sit in the green region: each earned more than A over the past 5 years with smaller price swings. That is 30% of the 3,633 screened.
- Among those with at least half A's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 19% less than A's 30.6%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.24 for A.
- Among A's popular alternatives, AMGN is in the region. AMGN earned 19.6% a year against 2.6% a year for A, at 24.9% volatility, 19% less than A's 30.6%.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to A; faint dots are 91 more of the 1,074 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
- Others in the green region
Is there a better investment than A?
Investments that beat A over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among A's popular alternatives, AMGN earned more than A with less volatility over the past 5 years: 19.6% a year at 24.9% volatility, against 2.6% a year at 30.6%.
- Looking beyond its popular alternatives, JNJ (pharmaceuticals) and NVS (pharmaceuticals) earned more than A with less volatility over the past 5 years. JNJ returned 12.7% a year at 17.9% volatility, against 2.6% a year at 30.6%.
- Simply owning the S&P 500 would have done better over the past 5 years: 12.7% a year at 17.1% volatility, against 2.6% at 30.6% for A.
How this works
The table below lists investments that beat A over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks A's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than A follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than A's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× A's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than A's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with A?lower diversifies more | Expenseper year | |||
| +2.6% | 30.6% | 0.24 | −43.2% | +306% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.64 | 0.09% | |||
| Popular alternativesbest 2 shownThe investments people most often weigh against A. 2 of 18 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.29 | — | ||
| Higher return, similar volatilityHigher Sharpe, smaller worst decline | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.19 | — | ||
| Same and neighboring categories, and shared themesbest 6 shownEverything else in Life Sciences Tools and the categories next to it (Biotechnology, Medical Diagnostics, Contract Research, Pharmaceuticals), plus A's specific themes. 22 of 85 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.23 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.20 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.32 | — | ||
EXELExelixis, Inc. · Biotechnology | Higher return in most periods | +24.4% | 35.8% | 0.79 | −57.2% | +448% | 0.09 | — | |
| Higher return, similar volatility | +22.6% | 29.1% | 0.85 | −41.6% | +521% | 0.06 | — | ||
RDYDr. Reddy's Laboratories Limited · Pharmaceuticals | Similar return, lower volatility | +1.7% | 23.7% | 0.19 | −40.5% | +59.4% | 0.20 | — | |
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 1,441 of 3,530 passed at least one test. | |||||||||
CIBRFirst Trust Nasdaq Cybersecurity ETF · Cybersecurity | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +14.1% | 26.1% | 0.64 | −33.9% | +454% | 0.48 | 0.58% | |
| On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst decline | +3.8% | 0.3% | 13.25 | −0.3% | — | 0.02 | 0.09% | ||
NHCNational HealthCare Corporation · Medical - Care Facilities | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +32.0% | 28.5% | 1.12 | −35.3% | +394% | 0.32 | — | |
JAAAJanus Henderson AAA CLO ETF · CLO Bonds | On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst decline | +5.1% | 1.7% | 2.98 | −2.6% | — | 0.19 | 0.20% | |
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.36 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +11.5% | 17.5% | 0.71 | −35.0% | +302% | 0.65 | 0.03% | ||
| On the frontierHigher return, similar volatilityHigher return in most periods | +51.2% | 33.4% | 1.41 | −79.7% | +1,387% | 0.31 | — | ||
| Similar return, lower volatilityHigher Sharpe, smaller worst decline | +2.7% | 2.9% | 0.94 | −6.3% | +32.7% | 0.28 | 0.03% | ||
What these numbers mean for A
- Annual return
- A returned 2.6% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $11,400. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- A's volatility over the past 5 years was 30.6%, 1.8 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, A's return lands within 30.6% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- A's Sharpe ratio over the past 5 years was 0.24, against 0.79 for the S&P 500, so A earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- A's worst fall from a peak to a low over the past 10 years was 43.2%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 43.2% fall takes a 76.0% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, A's monthly returns had a correlation of 0.64 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against A instead: the lower it is, the more that option would diversify a A holding. Guide: Correlation and diversification →
Show all 1,074 stocks and funds worth at least $500 million that earned more than A with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with A | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CIBRFirst Trust Nasdaq Cybersecurity ETF · Cybersecurity | Whole market | +14.1% | 26.1% | 0.64 | −33.9% | +454% | 0.48 | 0.58% |
| 2 | Whole market | +3.8% | 0.3% | 13.25 | −0.3% | — | 0.02 | 0.09% | |
| 3 | NHCNational HealthCare Corporation · Medical - Care Facilities | Whole market | +32.0% | 28.5% | 1.12 | −35.3% | +394% | 0.32 | — |
| 4 | JAAAJanus Henderson AAA CLO ETF · CLO Bonds | Whole market | +5.1% | 1.7% | 2.98 | −2.6% | — | 0.19 | 0.20% |
| 5 | Whole market | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.36 | — | |
| 6 | Whole market | +11.5% | 17.5% | 0.71 | −35.0% | +302% | 0.65 | 0.03% | |
| 7 | Whole market | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.64 | 0.03% | |
| 8 | Whole market | +20.8% | 22.6% | 0.96 | −25.7% | +508% | 0.06 | — | |
| 9 | Whole market | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.29 | — | |
| 10 | Whole market | +12.8% | 22.9% | 0.64 | −36.4% | +429% | 0.38 | — | |
| 11 | VRIGInvesco Variable Rate Investment Grade ETF · Bonds | Whole market | +4.7% | 1.3% | 3.51 | −13.1% | +40.5% | 0.07 | 0.30% |
| 12 | LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | Whole market | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.38 | 0.40% |
| 13 | Whole market | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.24 | — | |
| 14 | BALTInnovator Defined Wealth Shield ETF · Crypto | Whole market | +6.3% | 3.3% | 1.85 | −4.9% | — | 0.57 | 0.69% |
| 15 | Whole market | +17.4% | 22.9% | 0.82 | −31.4% | +685% | 0.22 | — | |
| 16 | Whole market | +8.2% | 16.4% | 0.57 | −36.0% | +140% | 0.55 | 0.05% | |
| 17 | Whole market | +14.5% | 23.0% | 0.71 | −35.1% | +553% | 0.53 | 0.18% | |
| 18 | Whole market | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.04 | — | |
| 19 | Whole market | +12.1% | 13.7% | 0.90 | −36.8% | +235% | 0.61 | 0.03% | |
| 20 | FLRTPacer Aristotle Pacific Floating Rate High Income ETF · Financials | Whole market | +6.0% | 2.3% | 2.55 | −21.0% | +58.0% | 0.30 | 0.60% |
| 21 | Whole market | +9.3% | 16.9% | 0.61 | −35.8% | +153% | 0.56 | 0.03% | |
| 22 | Whole market | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.09 | 0.40% | |
| 23 | Whole market | +5.1% | 18.3% | 0.37 | −23.8% | +145% | 0.16 | — | |
| 24 | Whole market | +11.5% | 20.9% | 0.63 | −32.6% | +394% | 0.33 | — | |
| 25 | Whole market | +18.4% | 26.0% | 0.78 | −35.1% | +779% | 0.54 | 0.09% | |
| 26 | Whole market | +21.3% | 25.6% | 0.89 | −30.3% | +816% | 0.01 | — | |
| 27 | Whole market | +10.4% | 14.1% | 0.78 | −31.7% | +258% | 0.65 | 0.04% | |
| 28 | FLOTiShares Floating Rate Bond ETF · Floating Rate Bonds | Whole market | +4.5% | 1.8% | 2.48 | −13.5% | +35.9% | 0.15 | 0.15% |
| 29 | Whole market | +24.2% | 22.8% | 1.07 | −32.4% | +406% | 0.30 | — | |
| 30 | Whole market | +9.7% | 14.3% | 0.72 | −33.4% | +252% | 0.53 | 0.06% | |
| 31 | Whole market | +12.2% | 29.0% | 0.54 | −37.5% | +464% | 0.30 | — | |
| 32 | Whole market | +17.2% | 24.9% | 0.77 | −30.4% | +285% | 0.25 | — | |
| 33 | Whole market | +11.1% | 24.2% | 0.56 | −36.7% | +204% | 0.09 | — | |
| 34 | Whole market | +10.3% | 16.2% | 0.69 | −34.2% | +223% | 0.64 | 0.06% | |
| 35 | Whole market | +5.2% | 17.5% | 0.38 | −36.4% | +102% | 0.41 | 0.06% | |
| 36 | Whole market | +5.2% | 8.9% | 0.61 | −25.4% | +37.8% | 0.16 | — | |
| 37 | Whole market | +11.2% | 20.8% | 0.62 | −37.4% | +319% | -0.04 | — | |
| 38 | Whole market | +13.9% | 18.5% | 0.80 | −34.0% | +446% | 0.14 | — | |
| 39 | Whole market | +5.5% | 21.5% | 0.36 | −30.1% | +89.8% | 0.32 | — | |
| 40 | PJULInnovator U.S. Equity Power Buffer ETF · Broad Market | Whole market | +10.5% | 8.6% | 1.20 | −18.2% | — | 0.61 | 0.79% |
| 41 | Whole market | +14.8% | 23.6% | 0.71 | −32.8% | +625% | 0.31 | — | |
| 42 | Whole market | +9.3% | 19.2% | 0.56 | −30.1% | +344% | 0.03 | — | |
| 43 | FJANFT Vest U.S. Equity Buffer ETF - January · Multi-Asset | Whole market | +11.1% | 10.5% | 1.05 | −13.6% | — | 0.59 | 0.85% |
| 44 | Whole market | +7.5% | 18.0% | 0.50 | −37.4% | +132% | 0.22 | — | |
| 45 | Whole market | +12.4% | 20.2% | 0.68 | −32.9% | +185% | 0.25 | — | |
| 46 | Whole market | +17.9% | 26.1% | 0.76 | −37.9% | +314% | 0.35 | — | |
| 47 | NEARiShares Short Duration Bond Active ETF · Short-Term Bonds | Whole market | +3.9% | 1.4% | 2.71 | −9.6% | +31.8% | 0.23 | 0.25% |
| 48 | Whole market | +15.8% | 24.6% | 0.72 | −30.7% | +576% | 0.18 | — | |
| 49 | Whole market | +13.1% | 22.4% | 0.67 | −34.5% | +451% | 0.55 | 0.04% | |
| 50 | Whole market | +14.7% | 17.5% | 0.87 | −34.7% | — | 0.62 | 0.26% | |
| 51 | Whole market | +7.2% | 19.2% | 0.46 | −29.0% | +68.8% | 0.18 | — | |
| 52 | Whole market | +5.4% | 21.8% | 0.35 | −34.3% | +240% | 0.30 | — | |
| 53 | Whole market | +6.7% | 21.4% | 0.41 | −37.9% | +208% | 0.44 | — | |
| 54 | Whole market | +7.6% | 26.1% | 0.41 | −37.8% | +188% | 0.08 | — | |
| 55 | Whole market | +7.5% | 11.0% | 0.71 | −13.7% | — | 0.55 | 0.35% | |
| 56 | VNLAJanus Henderson Short Duration Income ETF · Bonds | Whole market | +4.0% | 1.1% | 3.77 | −4.5% | — | 0.33 | 0.25% |
| 57 | FLTRVanEck IG Floating Rate ETF · Multi-Asset | Whole market | +4.8% | 2.1% | 2.20 | −17.8% | +41.8% | 0.06 | 0.14% |
| 58 | Whole market | +12.0% | 18.8% | 0.70 | −30.9% | +114% | 0.09 | — | |
| 59 | Whole market | +8.4% | 15.3% | 0.60 | −28.4% | +202% | 0.61 | 0.08% | |
| 60 | FLRNState Street SPDR Bloomberg Investment Grade Floating Rate ETF · Bonds | Whole market | +4.5% | 1.7% | 2.58 | −14.7% | +35.9% | 0.18 | 0.15% |
| 61 | ATOAtmos Energy Corporation · Gas Utilities | Whole market | +14.9% | 18.4% | 0.85 | −32.9% | +194% | 0.23 | — |
| 62 | CHTChunghwa Telecom Co., Ltd. · Integrated Telecommunications | Whole market | +7.7% | 13.3% | 0.63 | −23.8% | +101% | 0.26 | — |
| 63 | SPMOInvesco S&P 500 Momentum ETF · US Momentum Equity | Whole market | +18.7% | 20.8% | 0.93 | −30.9% | +499% | 0.55 | 0.13% |
| 64 | DFIVDimensional - International Value ETF · International Equity | Whole market | +14.8% | 16.4% | 0.93 | −25.4% | — | 0.46 | 0.27% |
| 65 | Whole market | +6.5% | 20.9% | 0.41 | −34.4% | +156% | 0.11 | — | |
| 66 | FLDRFidelity Low Duration Bond Factor ETF · Bonds | Whole market | +3.9% | 1.2% | 3.09 | −12.2% | — | 0.34 | 0.15% |
| 67 | AVLVAvantis U.S. Large Cap Value ETF · US Large-Cap Value | Whole market | +14.0% | 16.9% | 0.86 | −19.5% | — | 0.61 | 0.15% |
| 68 | Same or nearby category | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.23 | — | |
| 69 | HYGHiShares Interest Rate Hedged High Yield Bond ETF · Bonds | Whole market | +6.6% | 7.1% | 0.94 | −23.9% | +74.5% | 0.56 | 1.12% |
| 70 | Whole market | +6.1% | 20.0% | 0.40 | −31.6% | +270% | 0.15 | — | |
| 71 | HDViShares Core High Dividend ETF · US Dividend Equity | Whole market | +12.9% | 13.0% | 1.00 | −37.0% | +172% | 0.40 | 0.08% |
| 72 | TBUXT. Rowe Price Ultra Short-Term Bond ETF · Bonds | Whole market | +4.1% | 1.1% | 3.85 | −1.8% | — | 0.24 | 0.17% |
| 73 | NINiSource Inc · Gas Utilities | Whole market | +15.1% | 20.3% | 0.80 | −30.9% | +158% | 0.17 | — |
| 74 | WECWEC Energy Group, Inc. · Electric Utilities | Whole market | +7.2% | 19.0% | 0.46 | −32.3% | +159% | 0.23 | — |
| 75 | DFATDimensional - US Targeted Value ETF · US Small-Cap Equity | Whole market | +9.6% | 21.0% | 0.54 | −26.1% | — | 0.57 | 0.33% |
| 76 | FTSFortis Inc. · Electric Utilities | Whole market | +8.4% | 16.4% | 0.58 | −34.3% | +154% | 0.18 | — |
| 77 | Same or nearby category | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.20 | — | |
| 78 | USMViShares MSCI USA Min Vol Factor ETF · US Low-Volatility Equity | Whole market | +7.6% | 12.3% | 0.66 | −33.1% | +176% | 0.57 | 0.15% |
| 79 | AVEMAvantis Emerging Markets Equity ETF · Emerging Markets Equity | Whole market | +9.3% | 19.5% | 0.56 | −36.0% | — | 0.44 | 0.33% |
| 80 | Same or nearby category | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.32 | — | |
| 81 | SPHQInvesco S&P 500 Quality ETF · US Quality Equity | Whole market | +12.0% | 16.7% | 0.76 | −31.6% | +300% | 0.55 | 0.20% |
| 82 | PKGPackaging Corporation of America · Packaging | Whole market | +15.4% | 25.8% | 0.69 | −38.2% | +294% | 0.27 | — |
| 83 | AEEAmeren Corporation · Electric Utilities | Whole market | +7.9% | 19.4% | 0.49 | −29.1% | +192% | 0.21 | — |
| 84 | DTMDT Midstream, Inc. · Oil & Gas Midstream | Whole market | +24.5% | 25.2% | 1.00 | −23.6% | — | 0.20 | — |
| 85 | EXPDExpeditors International of Washington, Inc. · Freight & Logistics | Whole market | +12.0% | 27.1% | 0.56 | −35.6% | +349% | 0.58 | — |
| 86 | RAVINorthern Trust Ultra-Short Fixed Income ETF · Bonds | Whole market | +3.8% | 1.4% | 2.61 | −3.7% | +30.8% | 0.21 | 0.26% |
| 87 | EWJiShares MSCI Japan ETF · International Equity | Whole market | +9.2% | 18.8% | 0.57 | −33.1% | +132% | 0.55 | 0.49% |
| 88 | WTWWillis Towers Watson Public Limited Company · Insurance | Whole market | +6.9% | 23.9% | 0.40 | −32.9% | +187% | 0.24 | — |
| 89 | XLUState Street Utilities Select Sector SPDR ETF · Utilities Equity | Whole market | +7.8% | 17.4% | 0.52 | −36.0% | +138% | 0.29 | 0.08% |
| 90 | SDYState Street SPDR S&P Dividend ETF · US Dividend Equity | Whole market | +7.6% | 14.0% | 0.59 | −36.7% | +157% | 0.53 | 0.35% |
| 91 | BUFRFT Vest Laddered Buffer ETF · Buffered Equity | Whole market | +9.9% | 10.5% | 0.96 | −13.7% | — | 0.64 | 0.10% |
| 92 | Whole market | +17.3% | 18.2% | 0.97 | −40.0% | +352% | 0.43 | — | |
| 93 | RWLInvesco S&P 500 Revenue ETF · US Large-Cap Equity | Whole market | +13.7% | 14.4% | 0.97 | −36.1% | +287% | 0.63 | 0.39% |
| 94 | CHDChurch & Dwight Co., Inc. · Household & Personal Products | Whole market | +6.1% | 21.1% | 0.39 | −31.7% | +154% | 0.14 | — |
| 95 | DBEFXtrackers MSCI EAFE Hedged Equity ETF · International Equity | Whole market | +13.1% | 13.8% | 0.96 | −32.5% | +206% | 0.55 | 0.35% |
| 96 | HACKAmplify Cybersecurity ETF · Technology | Whole market | +12.6% | 25.8% | 0.59 | −38.7% | +373% | 0.51 | 0.60% |
| 97 | BKLNInvesco Senior Loan ETF · Bank Loans | Whole market | +5.4% | 4.5% | 1.19 | −24.1% | +50.7% | 0.43 | 0.67% |
| 98 | IOOiShares Global 100 ETF · Global Equity | Whole market | +15.7% | 17.2% | 0.94 | −31.4% | +361% | 0.60 | 0.40% |
| 99 | CMSCMS Energy Corporation · Electric Utilities | Whole market | +5.6% | 19.0% | 0.38 | −29.6% | +123% | 0.11 | — |
| 100 | JQUAJPMorgan U.S. Quality Factor ETF · US Quality Equity | Whole market | +13.6% | 15.7% | 0.89 | −32.9% | — | 0.66 | 0.12% |
A against its popular alternatives
The investments people most often weigh against A, compared period by period and year by year.
How do A's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at A, which divides the map into what did better or worse on each measure.
- Only AMGN and TMO were both more rewarding and calmer than A over the past 5 years, earning a higher annual return with lower volatility.
- 11 of the 18 popular alternatives earned less than A over the past 5 years while swinging more, the weaker corner of the map.
- Over the past 5 years, A returned 2.6% a year, less than the S&P 500's 12.7%, with higher volatility (30.6% against 17.1%).
Green points earned more than A with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| LLY Eli Lilly and Company | +40.7% | 32.8% |
| MEDP Medpace Holdings, Inc. | +27.1% | 52.0% |
| AMGN Amgen Inc. | +19.6% | 24.9% |
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| WAT Waters Corporation | +4.5% | 33.9% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| A This pageAgilent Technologies, Inc. | +2.6% | 30.6% |
| MTD Mettler-Toledo International Inc. | +2.6% | 32.5% |
| IQV IQVIA Holdings Inc. | +1.3% | 34.7% |
| QGEN Qiagen N.V. | +0.6% | 26.9% |
| RVTY Revvity, Inc. | −2.2% | 35.1% |
| DHR Danaher Corporation | −3.8% | 29.1% |
| CRL Charles River Laboratories International, Inc. | −5.6% | 43.9% |
| BRKR Bruker Corporation | −6.3% | 44.3% |
| ILMN Illumina, Inc. | −7.8% | 46.9% |
| TECH Bio-Techne Corporation | −10.2% | 39.4% |
| BIO Bio-Rad Laboratories, Inc. | −13.9% | 37.9% |
| TXG 10x Genomics, Inc. | −15.1% | 70.8% |
| AVTR Avantor, Inc. | −15.5% | 41.0% |
| PACB Pacific Biosciences of California, Inc. | −40.0% | 97.0% |
Has A consistently beaten its popular alternatives?
This section compares A with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than A helps separate lasting outperformance from a single strong stretch.
- Only one of the 18 popular alternatives, AMGN, outperformed A in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- LLY, AMGN and MEDP earned more for the risk they took than A (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.
- MEDP outperformed A over all three long-term periods but in none of the five short-term ones, so A has had the better of it lately.
A green cell means the alternative earned more than A over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| A Agilent Technologies, Inc. (this page) | — | +7.1% | +33.1% | +43.6% | +26.4% | +22.0% | +62.1% | +13.8% | +306% | 30.6% | 0.24 | −43.2% | — | $49B | — |
| AMGN QualifiedAmgen Inc. | 3/5 short2/3 long | +11.6% | +21.2% | +27.0% | +36.7% | +48.7% | +72.2% | +145% | +266% | 24.9% | 0.85 | −24.9% | — | $237B | — |
| LLY Drug Manufacturers - GeneralEli Lilly and Company | 2/5 short3/3 long | +10.2% | +12.1% | +40.0% | +19.4% | +59.7% | +124% | +451% | +1,807% | 32.8% | 1.21 | −34.5% | — | $1.2T | — |
| MEDP Medical - Diagnostics & ResearchMedpace Holdings, Inc. | 0/5 short3/3 long | −0.3% | +17.9% | +17.8% | +9.0% | +14.3% | +172% | +231% | +1,914% | 52.0% | 0.70 | −42.9% | — | $17B | — |
| TMO Medical - Diagnostics & ResearchThermo Fisher Scientific Inc. | 1/5 short2/3 long | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| WAT Medical - Diagnostics & ResearchWaters Corporation | 1/5 short2/3 long | +4.5% | +23.9% | +31.9% | +15.9% | +29.0% | +74.6% | +24.4% | +182% | 33.9% | 0.30 | −44.3% | — | $43B | — |
| CRL Medical - Diagnostics & ResearchCharles River Laboratories International, Inc. | 5/5 short1/3 long | +13.1% | +43.6% | +70.0% | +55.8% | +71.3% | +70.1% | −25.1% | +280% | 43.9% | 0.09 | −78.2% | — | $15B | — |
| ILMN Medical - Diagnostics & ResearchIllumina, Inc. | 5/5 short1/3 long | +12.2% | +45.1% | +102% | +99.4% | +169% | +130% | −33.3% | +93.0% | 46.9% | 0.06 | −86.2% | — | $40B | — |
| TXG Biotechnology10x Genomics, Inc. | 4/5 short1/3 long | −9.7% | +65.3% | +191% | +330% | +444% | +81.2% | −55.8% | — | 70.8% | 0.12 | −96.5% | — | $9.3B | — |
| RVTY Medical - Diagnostics & ResearchRevvity, Inc. | 5/5 short0/3 long | +8.6% | +46.6% | +67.8% | +59.3% | +64.0% | +54.6% | −10.6% | +203% | 35.1% | 0.11 | −59.0% | — | $17B | — |
| AVTR Medical - Instruments & SuppliesAvantor, Inc. | 4/5 short0/3 long | +10.1% | +55.9% | +95.5% | +45.0% | +9.5% | −19.1% | −56.9% | — | 41.0% | -0.20 | −83.2% | — | $11B | — |
| IQV Medical - Diagnostics & ResearchIQVIA Holdings Inc. | 2/5 short0/3 long | −0.8% | +31.4% | +51.5% | +18.8% | +26.3% | +45.3% | +6.5% | +260% | 34.7% | 0.21 | −51.5% | — | $44B | — |
| PACB Medical - DevicesPacific Biosciences of California, Inc. | 2/5 short0/3 long | +44.1% | +44.1% | +12.6% | +6.5% | −1.0% | −73.5% | −92.2% | −77.9% | 97.0% | -0.04 | −98.2% | — | $609M | — |
| MTD Medical - Diagnostics & ResearchMettler-Toledo International Inc. | 1/5 short0/3 long | +14.2% | +28.3% | +23.4% | +15.8% | +20.4% | +60.2% | +13.7% | +298% | 32.5% | 0.24 | −43.5% | — | $33B | — |
| BRKR Medical - DevicesBruker Corporation | 1/5 short0/3 long | −9.2% | −0.3% | +36.3% | +16.6% | +47.4% | −5.0% | −27.7% | +171% | 44.3% | 0.08 | −68.7% | — | $8.5B | — |
| QGEN Medical - Diagnostics & ResearchQiagen N.V. | 1/5 short0/3 long | +9.2% | +20.8% | +20.2% | +8.7% | +6.3% | +45.9% | +3.0% | +111% | 26.9% | 0.15 | −41.4% | — | $10B | — |
| DHR Medical - Diagnostics & ResearchDanaher Corporation | 0/5 short0/3 long | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| TECH BiotechnologyBio-Techne Corporation | 0/5 short0/3 long | +0.2% | +1.4% | +20.2% | +22.2% | +16.7% | +15.1% | −41.4% | +191% | 39.4% | -0.08 | −67.2% | — | $11B | — |
| BIO Medical - DevicesBio-Rad Laboratories, Inc. | 0/5 short0/3 long | −6.0% | +17.4% | +16.9% | +16.1% | +10.1% | +14.1% | −52.5% | +115% | 37.9% | -0.21 | −73.8% | — | $9.5B | — |
How did A do year by year?
This table shows each investment's total return in every full calendar year since 2000, along with where A ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with A and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- A finished ahead of the S&P 500 in 12 of its 26 full calendar years, and behind it in each of the last three.
- Among its popular alternatives, MEDP came out ahead of A most often, in eight of the nine years both traded.
- Ranked against its popular alternatives each year, A finished in the top quarter in six of 26 years and in the bottom quarter in six. In 2025, it ranked 12 of 19.
Newest year first. Green marks a year in which the fund came out ahead of A; gray means the two finished within a fraction of a point. The rank row places A among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of A | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A This pageAgilent Technologies, Inc. | — | +1.9% | −2.7% | −6.4% | −5.5% | +35.5% | +39.8% | +27.5% | +1.7% | +48.3% | +10.2% | +3.5% | +0.8% | +41.1% | +18.4% | −15.7% | +33.4% | +98.7% | −57.4% | +5.4% | +11.1% | +38.1% | −17.6% | +62.8% | −37.0% | −47.9% | −29.2% |
| Rank among alternatives | Top quarter in 6 of 26 | 12 of 19 | 11 of 19 | 13 of 19 | 4 of 19 | 13 of 19 | 13 of 19 | 11 of 17 | 13 of 17 | 3 of 17 | 6 of 16 | 15 of 16 | 12 of 16 | 5 of 15 | 11 of 15 | 8 of 15 | 4 of 14 | 2 of 14 | 12 of 14 | 13 of 14 | 9 of 14 | 3 of 14 | 13 of 14 | 4 of 14 | 8 of 14 | 13 of 14 | 11 of 11 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 13 of 26 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% | −9.8% |
| AMGN Amgen Inc. | 13 of 26 | +29.7% | −6.8% | +13.5% | +20.4% | +0.9% | −2.0% | +27.6% | +15.2% | +22.3% | −7.6% | +4.0% | +42.3% | +34.8% | +36.8% | +18.2% | −3.0% | −2.0% | +24.3% | −32.0% | −13.4% | +22.9% | +3.8% | +27.8% | −14.4% | −11.7% | +6.5% |
| LLY Eli Lilly and Company | 14 of 26 | +40.3% | +33.3% | +60.9% | +34.3% | +66.1% | +31.0% | +16.2% | +40.5% | +17.8% | −10.4% | +25.4% | +39.8% | +7.3% | +24.2% | +25.2% | +3.6% | −6.2% | −21.3% | +5.7% | −5.2% | +2.6% | −17.6% | +13.1% | −17.6% | −14.4% | +41.9% |
| MEDP Medpace Holdings, Inc. | 8 of 9 | +69.1% | +8.4% | +44.3% | −2.4% | +56.4% | +65.6% | +58.8% | +46.0% | +0.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| TMO Thermo Fisher Scientific Inc. | 18 of 26 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% | +13.8% | +13.1% | +75.8% | +43.2% | −18.8% | +16.1% | +40.0% | −40.9% | +27.4% | +50.3% | −0.2% | +19.8% | +25.3% | −15.7% | +5.6% | +98.2% |
| WAT Waters Corporation | 11 of 26 | +2.4% | +12.7% | −3.9% | −8.1% | +50.6% | +5.9% | +23.9% | −2.4% | +43.8% | −0.1% | +19.4% | +12.7% | +14.8% | +17.6% | −4.7% | +25.4% | +69.1% | −53.6% | +61.5% | +29.5% | −19.2% | +41.1% | +52.3% | −43.8% | −53.6% | +215% |
| CRL Charles River Laboratories International, Inc. | 13 of 25 | +8.1% | −21.9% | +8.5% | −42.2% | +50.8% | +63.6% | +35.0% | +3.4% | +43.6% | −5.2% | +26.3% | +20.0% | +41.5% | +37.1% | −23.1% | +5.5% | +28.6% | −60.2% | +52.1% | +2.1% | −7.9% | +34.0% | −10.8% | +14.9% | +22.3% | — |
| ILMN Illumina, Inc. | 15 of 25 | −1.8% | −1.3% | −31.1% | −46.9% | +2.8% | +11.5% | +10.6% | +37.3% | +70.7% | −33.3% | +4.0% | +66.9% | +99.0% | +82.4% | −51.9% | +106% | +17.8% | −12.1% | +50.8% | +179% | +48.6% | +34.4% | +109% | −71.3% | −26.9% | — |
| TXG 10x Genomics, Inc. | 3 of 6 | +13.6% | −74.3% | +53.6% | −75.5% | +5.2% | +85.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| RVTY Revvity, Inc. | 13 of 26 | −13.1% | +2.4% | −21.9% | −30.1% | +40.4% | +48.2% | +24.0% | +7.8% | +40.8% | −2.1% | +23.2% | +6.8% | +31.0% | +60.4% | −21.6% | +27.1% | +50.6% | −45.9% | +18.4% | −4.5% | +6.2% | +33.9% | +112% | −75.7% | −32.7% | +154% |
| AVTR Avantor, Inc. | 3 of 6 | −45.6% | −7.7% | +8.3% | −50.0% | +49.7% | +55.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| IQV IQVIA Holdings Inc. | 8 of 12 | +14.7% | −15.1% | +12.9% | −27.4% | +57.5% | +16.0% | +33.0% | +18.7% | +28.7% | +10.8% | +16.6% | +27.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| PACB Pacific Biosciences of California, Inc. | 6 of 15 | +2.2% | −81.3% | +19.9% | −60.0% | −21.1% | +405% | −30.5% | +180% | −30.5% | −71.1% | +67.5% | +49.9% | +208% | −39.3% | −82.4% | — | — | — | — | — | — | — | — | — | — | — |
| MTD Mettler-Toledo International Inc. | 17 of 26 | +13.9% | +0.9% | −16.1% | −14.8% | +48.9% | +43.7% | +40.3% | −8.7% | +48.0% | +23.4% | +12.1% | +24.7% | +25.5% | +30.9% | −2.3% | +44.0% | +55.8% | −40.8% | +44.3% | +42.8% | +7.6% | +21.6% | +31.7% | −38.2% | −4.7% | +42.4% |
| BRKR Bruker Corporation | 12 of 25 | −19.3% | −20.0% | +7.8% | −18.3% | +55.3% | +6.6% | +71.8% | −12.8% | +62.7% | −12.2% | +23.7% | −0.8% | +29.8% | +22.7% | −25.2% | +37.7% | +199% | −69.7% | +77.1% | +54.5% | +20.7% | −11.5% | −6.4% | −70.3% | −30.6% | — |
| QGEN Qiagen N.V. | 13 of 26 | +12.5% | +2.6% | −12.9% | −10.3% | +5.2% | +56.4% | −1.9% | +11.4% | +10.7% | +1.3% | +17.8% | −1.5% | +31.2% | +31.4% | −29.3% | −12.4% | +27.1% | −16.5% | +39.1% | +28.8% | +7.3% | −8.5% | +131% | −72.1% | −46.3% | +83.3% |
| DHR Danaher Corporation | 18 of 26 | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% | +9.3% | +11.6% | +38.3% | +19.1% | −0.1% | +25.7% | +33.0% | −35.4% | +21.3% | +30.1% | −2.7% | +25.3% | +39.7% | +9.1% | −11.7% | +41.5% |
| TECH Bio-Techne Corporation | 13 of 26 | −17.9% | −6.3% | −6.5% | −35.7% | +63.4% | +45.4% | +52.7% | +12.6% | +27.5% | +15.8% | −1.3% | −1.1% | +40.9% | +1.9% | +5.5% | −2.5% | +8.0% | −1.9% | +19.2% | −1.2% | +44.3% | +2.8% | +32.5% | −22.4% | +2.0% | +31.1% |
| BIO Bio-Rad Laboratories, Inc. | 13 of 26 | −7.8% | +1.7% | −23.2% | −44.4% | +29.6% | +57.5% | +59.4% | −2.7% | +30.9% | +31.5% | +15.0% | −2.5% | +17.7% | +9.4% | −7.5% | +7.7% | +28.1% | −27.3% | +25.6% | +26.1% | +14.1% | −0.5% | +49.0% | +22.3% | +99.1% | +36.0% |
Risk and diversification
How A has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were A's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents A's five deepest drawdowns since it began trading in 1999, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- In all five of A's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: A fell 43.2% from September 2021 to April 2025, while the S&P 500 rose 15.6%.
- The slowest recovery came after A fell 93.2% from March 2000 to October 2002; it did not regain that peak until August 2020, 18 years later.
Green means A fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | A fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| Dot-com bust | −93.3% | −40.3% | Mar 2000 | Oct 2002 | 2.6 years | Aug 2020 | 17.8 years |
| 2022 bear market | −43.2% | +15.6% | Sep 2021 | Apr 2025 | 3.6 years | Sep 2026 | 17 months |
| No named crash | −24.9% | −6.1% | Dec 1999 | Jan 2000 | 1 month | Feb 2000 | 1 month |
| No named crash | −11.6% | −4.0% | Feb 2021 | Mar 2021 | 1 month | Apr 2021 | 1 month |
| No named crash | −9.0% | +0.1% | Dec 1999 | Dec 1999 | Under a month | Dec 1999 | Under a month |
How did A do in stock market crashes?
This section measures how far A, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
- A fell further than the S&P 500 in seven of the ten crashes it has traded through. The clearest case was the dot-com bust, when A fell 92.4% and the S&P 500 fell 47.5%.
- Among its popular alternatives, AMGN held up best, falling less than A in nine of the ten crashes they both traded through.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than A.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A This pageAgilent Technologies, Inc. | — | −3.7% | −25.3% | −25.8% | −16.1% | −8.7% | −17.6% | −37.3% | −4.2% | −67.6% | −92.4% |
| SPY S&P 500State Street SPDR S&P 500 ETF | 7 of 10 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| AMGN Amgen Inc. | 9 of 10 | −1.2% | −11.9% | −18.3% | −14.3% | −7.4% | −22.1% | −12.6% | −0.5% | −31.3% | −60.2% |
| LLY Eli Lilly and Company | 8 of 10 | −0.6% | −11.7% | −16.9% | −10.2% | −8.6% | −19.6% | −10.9% | 0.0% | −50.0% | −54.3% |
| MEDP Medpace Holdings, Inc. | 1 of 5 | −11.9% | −36.4% | −39.5% | −26.1% | −2.1% | — | — | — | — | — |
| TMO Thermo Fisher Scientific Inc. | 8 of 10 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| WAT Waters Corporation | 7 of 10 | −1.6% | −26.3% | −25.3% | −14.7% | −9.7% | −16.6% | −26.4% | −3.4% | −60.7% | −80.1% |
| CRL Charles River Laboratories International, Inc. | 3 of 9 | −7.7% | −49.3% | −44.5% | −23.4% | −4.6% | −19.1% | −33.3% | −1.8% | −69.8% | — |
| ILMN Illumina, Inc. | 3 of 9 | −6.7% | −58.2% | −31.0% | −25.8% | −5.3% | −36.1% | −48.7% | −1.9% | −57.9% | — |
| TXG 10x Genomics, Inc. | 0 of 3 | −8.1% | −81.1% | −43.1% | — | — | — | — | — | — | — |
| RVTY Revvity, Inc. | 5 of 10 | −3.2% | −38.1% | −29.3% | −26.1% | −7.7% | −23.6% | −31.2% | −3.4% | −62.6% | −91.6% |
| AVTR Avantor, Inc. | 0 of 3 | −6.2% | −50.5% | −53.9% | — | — | — | — | — | — | — |
| IQV IQVIA Holdings Inc. | 1 of 6 | −6.8% | −35.9% | −48.9% | −19.2% | −5.3% | −28.7% | — | — | — | — |
| PACB Pacific Biosciences of California, Inc. | 0 of 7 | −6.7% | −79.3% | −47.4% | −28.1% | −10.0% | −34.7% | −75.2% | — | — | — |
| MTD Mettler-Toledo International Inc. | 5 of 10 | −3.8% | −33.9% | −23.8% | −17.7% | −10.0% | −16.9% | −21.5% | −4.3% | −60.6% | −53.7% |
| BRKR Bruker Corporation | 1 of 9 | −2.5% | −38.0% | −36.2% | −24.1% | −13.4% | −19.9% | −39.0% | −5.5% | −80.2% | — |
| QGEN Qiagen N.V. | 8 of 10 | −0.4% | −21.3% | −12.4% | −14.0% | −7.0% | −27.8% | −25.9% | −2.6% | −45.1% | −92.1% |
| DHR Danaher Corporation | 7 of 10 | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| TECH Bio-Techne Corporation | 6 of 10 | −3.6% | −39.6% | −23.5% | −34.8% | −4.5% | −24.9% | −18.8% | −0.4% | −43.8% | −69.6% |
| BIO Bio-Rad Laboratories, Inc. | 7 of 10 | −1.9% | −45.3% | −21.8% | −29.7% | −8.0% | −18.1% | −25.4% | −0.5% | −50.9% | −29.1% |
How closely does A move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares A with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- LLY took just 6% of the S&P 500's losses, against 141% for A, while still keeping 101% of its gains.
- Over the past 10 years, A captured 120% of the S&P 500's gains in rising months and 141% of its losses in falling months, with a beta of 1.13. It amplified the market's moves in both directions.
- Five of the 16 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than A's 0.85, led by LLY, MEDP and AMGN.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than A's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| A This pageAgilent Technologies, Inc. | 120% | 141% | 0.85 | 1.13 |
| LLY Eli Lilly and Company | 101% | 6% | 15.73 | 0.37 |
| MEDP Medpace Holdings, Inc. | 168% | 118% | 1.42 | 1.24 |
| AMGN Amgen Inc. | 74% | 64% | 1.16 | 0.54 |
| DHR Danaher Corporation | 84% | 84% | 1.01 | 0.75 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| MTD Mettler-Toledo International Inc. | 118% | 143% | 0.83 | 1.13 |
| WAT Waters Corporation | 107% | 139% | 0.77 | 1.01 |
| CRL Charles River Laboratories International, Inc. | 135% | 175% | 0.77 | 1.30 |
| IQV IQVIA Holdings Inc. | 128% | 167% | 0.77 | 1.31 |
| RVTY Revvity, Inc. | 111% | 146% | 0.76 | 1.10 |
| BRKR Bruker Corporation | 121% | 160% | 0.75 | 1.27 |
| QGEN Qiagen N.V. | 62% | 83% | 0.75 | 0.45 |
| TECH Bio-Techne Corporation | 120% | 162% | 0.74 | 1.23 |
| BIO Bio-Rad Laboratories, Inc. | 104% | 146% | 0.71 | 0.99 |
| ILMN Illumina, Inc. | 120% | 200% | 0.60 | 1.19 |
| PACB Pacific Biosciences of California, Inc. | 76% | 234% | 0.33 | 1.70 |
What diversifies A?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with A's. Because such investments tend not to fall at the same time, pairing A with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in A into GLD would have cut the portfolio's volatility by 18% over the past 5 years and raised its annual return (+2.5% for A alone, +6.4% for the mix).
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of A over the past 5 years, with correlations of 0.38 or lower, and each still earned a positive 5-year return.
- MCK made money in six of the nine calendar years in which A lost money.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which A lost money. The last two columns show a portfolio that is 80% A and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2023 | 2022 | 2011 | 2008 | 2004 | 2002 | 2001 | 2000 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A Agilent Technologies, Inc. (this page) | 1.00 | +13.8% | 0.24 | −2.7% | −6.4% | −5.5% | −15.7% | −57.4% | −17.6% | −37.0% | −47.9% | −29.2% | 29.4% | +2.5% |
| LVHI InternationalFranklin International Low Volatility High Dividend Index ETF | 0.38 | +119% | 1.48 | +15.9% | +17.4% | +3.8% | — | — | — | — | — | — | 24.3% | +5.9% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.28 | +225% | 1.34 | +29.8% | +42.0% | +6.0% | −16.1% | −20.8% | — | — | — | — | 24.3% | +7.7% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.32 | +101% | 1.04 | +33.4% | +8.0% | +10.4% | — | — | — | — | — | — | 24.6% | +5.7% |
| HDV Dividend & IncomeiShares Core High Dividend ETF | 0.40 | +83.3% | 1.00 | +14.1% | +1.8% | +7.1% | — | — | — | — | — | — | 24.8% | +5.0% |
| EWP Broad MarketiShares MSCI Spain ETF | 0.40 | +140% | 0.97 | +5.7% | +30.3% | −5.2% | −9.8% | −36.8% | +30.2% | −13.6% | −9.2% | −11.8% | 25.3% | +6.6% |
| SMH TechnologyVanEck Semiconductor ETF | 0.43 | +323% | 0.97 | +39.1% | +73.4% | −33.5% | +6.8% | −44.7% | −19.3% | −47.0% | −14.6% | — | 27.2% | +9.8% |
| GLD CommoditiesSPDR Gold Shares | 0.09 | +126% | 0.96 | +26.7% | +12.7% | −0.8% | +9.6% | +4.9% | — | — | — | — | 24.0% | +6.4% |
| XLE EnergyState Street Energy Select Sector SPDR ETF | 0.22 | +177% | 0.93 | +5.6% | −0.6% | +64.4% | +2.8% | −39.0% | +33.8% | −14.8% | −18.2% | +24.4% | 25.1% | +7.3% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2023 | 2022 | 2011 | 2008 | 2004 | 2002 | 2001 | 2000 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A Agilent Technologies, Inc. (this page) | 1.00 | +13.8% | 0.24 | −2.7% | −6.4% | −5.5% | −15.7% | −57.4% | −17.6% | −37.0% | −47.9% | −29.2% | 29.4% | +2.5% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.32 | +479% | 1.55 | +19.0% | +34.1% | +54.1% | +8.1% | −39.6% | −4.7% | −8.3% | −2.5% | +108% | 25.7% | +9.7% |
| CLS Hardware, Equipment & PartsCelestica Inc. | 0.27 | +3,143% | 1.47 | +215% | +160% | +1.3% | −24.4% | −20.5% | −6.4% | −65.1% | −25.6% | −2.3% | 29.0% | +21.5% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.30 | +1,636% | 1.46 | +107% | +79.6% | +17.0% | −17.0% | −15.2% | +40.0% | −9.4% | +73.7% | −71.1% | 27.5% | +17.8% |
| MCK Medical - DistributionMcKesson Corporation | 0.04 | +413% | 1.44 | +23.7% | +24.1% | +51.8% | +11.8% | −40.4% | −1.4% | −27.2% | +4.9% | +61.2% | 24.2% | +9.5% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.31 | +690% | 1.41 | −4.0% | +30.4% | +86.6% | — | — | — | — | — | — | 26.3% | +11.6% |
Common questions
What was A's worst drawdown?
A's deepest decline since it began trading in 1999 was 93.2%, from March 2000 to October 2002. It took about 18 years from the low to climb back to its old high.
What were A's best and worst years?
Over 26 full calendar years, A's best year was 2009, when it returned 98.7%. Its worst was 2008, with a return of -57.4%.
Is there a better investment than A?
Among A's popular alternatives, AMGN earned more than A with less volatility over the past 5 years: 19.6% a year at 24.9% volatility, against 2.6% a year at 30.6%. Looking beyond its popular alternatives, JNJ (pharmaceuticals) and NVS (pharmaceuticals) earned more than A with less volatility over the past 5 years. JNJ returned 12.7% a year at 17.9% volatility, against 2.6% a year at 30.6%.
Is A more volatile than the S&P 500?
Yes. A's volatility over the past 5 years was 30.6%, 1.8 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, A's return lands within 30.6% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is A's Sharpe ratio?
A's Sharpe ratio over the past 5 years was 0.24, against 0.79 for the S&P 500, so A earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is A with the S&P 500?
Over the past 5 years, A's monthly returns had a correlation of 0.64 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against A instead: the lower it is, the more that option would diversify a A holding.
What are the best alternatives to A?
Of the 18 popular alternatives we compared, one outperformed A in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: AMGN.
Did A outperform the S&P 500?
A finished ahead of the S&P 500 (SPY) in 12 of 26 full calendar years. In 2025, it returned +1.9%, against +17.7% for the index.
How did A do in stock market crashes?
A fell less than the S&P 500 (SPY) in two of the ten major crashes it has traded through, and further in seven. The clearest case was the dot-com bust, when A fell 92.4% and the S&P 500 fell 47.5%.
What diversifies A?
These had a low correlation with A over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.38), DXJ (correlation 0.28) and EMLP (correlation 0.32); among large stocks, CAH (correlation 0.32), CLS (correlation 0.27) and FIX (correlation 0.30). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than A's. Returns within 0.5 points or 3% of A's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.